SECURITIES AND EXCHANGE COMMISSION
	WASHINGTON, D.C.   20549

	SCHEDULE 13D

	Under the Securities Exchange Act of 1934



	BIOSENSOR CORPORATION
	(Name of Issuer)


	Series A Preferred Stock $.10 par value
	(Title of Class of Securities)



	090661-10-9
	(CUSIP Number)



	Ronald G. Moyer
	6 Woodcross Drive
	Columbia, South Carolina 29212
	(803) 407-3044
	(Name, Address and Telephone Number of Person
	Authorized to Receive Notices and Communications)


	July 23, 1998
	(Date of Event Which Requires Filing of this Statement)



If the filing person has previously filed a statement on Schedule 
13G to report the acquisition which is the subject of this Schedule 
13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), 
check the following box [  ].



1.	NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

Bernard B. Klawans		[217 18 9277]

2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a)	[   ]
(b)	[   ]

3.	SEC USE ONLY


4.	SOURCE OF FUNDS

00

5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS
IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)				[   ]

6.	CITIZENSHIP OR PLACE OF ORGANIZATION

Pennsylvania

7.	NUMBER OF SHARES BENEFICIALLY OWNED BY EACH
REPORTING PERSON WITH:

SOLE VOTING POWER

12,093.75

8.	SHARED VOTING POWER

- ----

9.	SOLE DISPOSITIVE POWER

12,093.75

10.	SHARED DISPOSITIVE POWER

- ----

11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON

12,093.75

12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)
EXCLUDES CERTAIN SHARES							[   ]

13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

8.1%

14.	TYPE OF REPORTING PERSON

IN

Item 1.  	Security and Issuer.

This Schedule 13D is filed on behalf of Bernard B. Klawans (the 
"Reporting Person"), relative to the $ .10 par value Series A Preferred Stock 
issued by Biosensor Corporation ("Biosensor").  The principal executive offices 
of Biosensor are located at 6 Woodcross Drive, Columbia, South Carolina 29212.

Item 2.	Identity and Background.

Reporting Person

(a)	Bernard B. Klawans;
(b)	1375 Anthony Wayne Drive, Wayne, PA 19087;
(c)	The principal occupation of the Reporting Person is the President of 
Valley Forge Fund Management Company, in the Valley Forge Fund 
principal executive offices located at 1375 Anthony Wayne Drive, 
Wayne, Pennsylvania 19087. Valley Forge Management Company manages 
mutual investment funds, including Valley Forge Fund, and provides 
various other financial services.
(d) and (e)   See below;
(f)	United States citizen.

During the last five years, the above (i) has not been convicted in a 
criminal proceeding (excluding traffic violations or similar misdemeanors), and 
(ii) was not party to a civil proceeding of a judicial or administrative body 
or of competent jurisdiction and as a result of such proceeding, was not or 
is not subject to a judgment, decree or final order enjoining future violations
of, or prohibiting or mandating activities subject to, Federal or State 
securities laws or finding any violation or respect to such laws.


Item 3.	Source and Amount of Funds or Other Consideration.

The Reporting Person acquired 12,093.75 shares of Series A Preferred 
Stock of Biosensor (the "Shares") on July 23, 1998, as a result of the share 
exchange, under applicable Minnesota law, between Biosensor and Carolina 
Medical, Inc. ("CMI"), in which Biosensor was the acquiring corporation (the 
"Share Exchange").  Prior to July 23, 1998, the Reporting Person owned 161,250 
shares of CMI common stock.  On July 23, 1998, the Share Exchange was 
consummated, and each share of CMI common stock was exchanged for .075 shares
of Series A Preferred Stock of Biosensor.  As a result of the Share Exchange,
the Reporting Person's 161,250 shares of CMI common stock were exchanged for
the Shares.

Item 4.	Purpose of the Transaction.

The Share Exchange was effected in order to obtain a reorganization of 
Biosensor's and CMI's respective businesses in order to enhance their ability
to provide quality products and services.  The Reporting Person intends to 
review continuously his investment in Biosensor and, on the basis of such 
review and such market and other factors as he may deem relevant, may sell the 
Shares or acquire additional shares of Biosensor's common or preferred stock.  
Additionally, assuming an increase in the number of shares of Biosensor's 
common stock is approved by Biosensor's shareholders, as discussed more 
particularly below, the Shares will be automatically converted into 1,161,000 
shares of Biosensor's common stock.

Following the Share Exchange, the following were named new directors of 
Biosensor:

Ronald G. Moyer
C. Roger Jones
L. John Ankney
Spencer M. Vawter
David Heiden

and one of the existing directors, Stephen L. Zuckerman, resigned.  The Board 
of Directors of Biosensor also appointed Ronald G. Moyer as Chief Executive 
Officer and President, B. Steven Springrose as Chief Technology Officer and 
Vice President, and Michael W. Oliver as Interim Chief Financial Officer.  

Biosensor is also in the process of issuing a proxy statement for a 
special meeting of its shareholders to vote upon the following matters:

1.	A proposal to amend Biosensor's Certificate of Incorporation to 
change the name of the Company to BIOTEL, Inc.

2.	A proposal to amend Biosensor's Certificate of Incorporation to 
effectuate a 1 for 6 reverse stock split of all outstanding shares of common 
stock of Biosensor (the "Reverse Stock Split").
3.	A proposal to amend Biosensor's Certificate of Incorporation to 
increase the amount of authorized common stock, following the effectuation of 
the Reverse Stock Split.

4.	A proposal to amend Biosensor's Certificate of Incorporation to 
authorize "blank check" preferred stock.

Biosensor also contemplates merging with Advanced Medical Products, Inc. 
("AMP").  Following the consummation of the Share Exchange, approximately 55% 
of the issued and outstanding shares of AMP is owned indirectly by Biosensor 
(directly owned by CMI).  If consummated, holders of common stock of AMP will 
receive 6 shares of Biosensor common stock (on a pre-Reverse Stock Split basis) 
in exchange for each 8 shares of common stock of AMP.  Completion of this 
merger is expected prior to October 1998.

Except as described in this Schedule 13D, including this Item 4, the 
Reporting Person has no plans or proposals which relate to or which would 
result in any events described in subsections (a) through (j) of Item 4 of the 
General Instructions to Schedule 13D.

Item 5.	Interest in Securities of the Issuer.

(a)	As of July 23, 1998, the Reporting Person beneficially owned 
12,093.75 shares (or approximately 8.1% of the outstanding shares) 
of Biosensor Series A Preferred Stock.

(b)	The Reporting Person will have sole power to vote and to dispose of 
the 12,093.75 shares.

(c)	As of July 23, 1998, and within the last 60 days, to the best 
knowledge and belief of the undersigned, other than as described 
herein, no transactions involving Biosensor  equity securities had 
been engaged in by the Reporting Person.

(d)	No other person is known to have the right to receive or the power 
to direct the receipt of dividends from, or the proceeds from the 
sale of the Shares.

Item 6.  	Contracts, Arrangements, Understandings or Relationships with Respect 
to Securities of the Issuer.
				None.

Item 7.	Material to be Filed as Exhibits.

1.	Filed herein by Reference as Exhibit A, the Plan of Reorganization 
and Agreement between Biosensor Corporation and Carolina Medical, Inc. dated 
May 29, 1998, filed with the Securities and Exchange Commission on July 31, 
1998 by Biosensor Corporation as Exhibit 1 to Form 8K dated July 23, 1998.

2.	Filed herein by Reference as Exhibit B, the Preliminary Proxy 
Statement (Special Meeting) filed with the Securities and Exchange Commission 
on June 2, 1998 by Biosensor Corporation on Schedule 14a.

After reasonable inquiry and to the best knowledge and belief of the 
undersigned, it is hereby certified that the information set forth in this 
statement is true, complete and correct.

Dated:  July 30, 1998					                      ______________			
							                                         Bernard B. Klawans



- - 5 -


C:\WINDOWS\DESKTOP\RON'S BRIEFCASE\SCH-13D2E.BIO.DOC/ kjs